Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current

被引:144
作者
Witchel, HJ
Hancox, JC
机构
[1] Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England
[2] Univ Bristol, Sch Med Sci, Cardiovasc Res Labs, Bristol BS8 1TD, Avon, England
来源
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY | 2000年 / 27卷 / 10期
关键词
cardiac arrhythmia; HERG; human ether-a-go-go-related gene; I-Kr; long QT syndrome; LQTS; potassium channel; rapidly activating delayed rectifier K+ current;
D O I
10.1046/j.1440-1681.2000.03337.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Long QT syndrome (LQTS) is a cardiac disorder characterized by syncope, seizures and sudden death; it can be congenital, idiopathic, or iatrogenic. 2. Long QT syndrome is so-named because of the connection observed between the distinctive polymorphic ventricular tachycardia torsade de pointes and prolongation of the QT interval of the electrocardiogram, reflecting abnormally slowed ventricular action potential (AP) repolarization. Acquired LQTS has many similar clinical features to congenital LQTS, but typically affects older individuals and is often associated with specific pharmacological agents. 3. A growing number of drugs associated with QT prolongation and its concomitant risks of arrhythmia and sudden death have been shown to block the 'rapid' cardiac delayed rectifier potassium current (I-Kr) or cloned channels encoded by the human ether-a-go-go-related gene (HERG; the gene believed to encode native I-Kr). Because I-Kr plays an important role in ventricular AP repolarization, its inhibition would be expected to result in prolongation of both the AP and QT interval of the electrocardiogram. 4. The drugs that produce acquired LQTS are structurally heterogeneous, including anti-arrhythmics, such as quinidine, non-sedating antihistamines, such as terfenadine, and psychiatric drugs, such as haloperidol. In addition to heterogeneity in their structure, the electrophysiological characteristics of HERG/I-Kr inhibition differ between agents. 5. Here, clinical observations are associated with cellular data to correlate acquired LQTS with the I-Kr/HERG potassium (K+) channel. One strategy for developing improved compounds in those drug classes that are currently associated with LQTS could be to design drug structures that preserve clinical efficacy but are modified to avoid pharmacological interactions with I-Kr. Until such time, awareness of the QT-prolongation risk of particular agents is important for the clinician.
引用
收藏
页码:753 / 766
页数:14
相关论文
共 163 条
[41]   QUINIDINE-INDUCED ACTION-POTENTIAL PROLONGATION, EARLY AFTERDEPOLARIZATIONS, AND TRIGGERED ACTIVITY IN CANINE PURKINJE-FIBERS - EFFECTS OF STIMULATION RATE, POTASSIUM, AND MAGNESIUM [J].
DAVIDENKO, JM ;
COHEN, L ;
GOODROW, R ;
ANTZELEVITCH, C .
CIRCULATION, 1989, 79 (03) :674-686
[42]  
DELPON E, 1991, N-S ARCH PHARMACOL, V344, P645
[43]   PROPAFENONE PREFERENTIALLY BLOCKS THE RAPIDLY ACTIVATING COMPONENT OF DELAYED RECTIFIER K+ CURRENT IN GUINEA-PIG VENTRICULAR MYOCYTES - VOLTAGE-INDEPENDENT AND TIME-DEPENDENT BLOCK OF THE SLOWLY ACTIVATING COMPONENT [J].
DELPON, E ;
VALENZUELA, C ;
PEREZ, O ;
CASIS, O ;
TAMARGO, J .
CIRCULATION RESEARCH, 1995, 76 (02) :223-235
[44]   Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans [J].
Demolis, JL ;
FunckBrentano, C ;
Ropers, J ;
Ghadanfar, M ;
Nichols, DJ ;
Jaillon, P .
CIRCULATION, 1996, 94 (07) :1592-1599
[45]   Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers [J].
Demolis, JL ;
Martel, C ;
FunckBrentano, C ;
Sachse, A ;
Weimann, HJ ;
Jaillon, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (04) :403-409
[46]  
Drolet B, 1999, J PHARMACOL EXP THER, V288, P1261
[47]  
DUAN D, 1993, J PHARMACOL EXP THER, V264, P1113
[48]  
DUKES ID, 1990, J PHARMACOL EXP THER, V254, P560
[49]  
Dumaine R, 1998, J PHARMACOL EXP THER, V286, P727
[50]   CARDIOVASCULAR EFFECTS OF PHENOTHIAZINES [J].
ELKAYAM, U ;
FRISHMAN, W .
AMERICAN HEART JOURNAL, 1980, 100 (03) :397-401